Topic: galantamine

The delivery of molecules like galantamine and DNA aptamers to the brain for the treatment of neurodegenerative diseases is a great challenge because of the blood-brain barrier selectivity. However, nanoliposomal systems can provide an alternative to this drawback. This study aimed to design and develop nanoliposomes based on soy lecithin loaded with galantamine (acetylcholinesterase inhibitor) or DNA aptamers designed to hinder the aggregation of proteins like Aβ, TDP-43 and α-synuclein. For this, a complete physicochemical characterization of soy lecithin and other raw materials was carried

Depressive disorders are the leading cause of the neuropsychiatric disparity, and the lack of understanding of the causes and treatment of these disorders progresses toward therapeutic failure. Current treatment approaches only provide symptomatic relief but fail to cure the underlying pathophysiology. The present study aimed to investigate the antidepressant effect of escitalopram (ESC) and galantamine (GAL) combination in vivo on a chronic unpredictable mild stress (CUMS)-induced depression in mice and further explored its mechanism of action around cAMP, BDNF-related neurotrophic signaling,

Nicotinic acetylcholine receptors (nAChRs) are pentameric ionotropic receptors composed of a combination of α and β subunits. Human genetic association and preclinical studies have shown a key role of α5 containing nAChRs (α5*nAChRs) in the risk to develop nicotine addiction. Tobacco smoking is highly comorbid with bulimia nervosa and binge eating disorders. Interestingly, genetic variation at CHRNA5 has also been associated with higher body mass index (BMI) in never smokers, but lower BMI in current smokers, and increased appetence for food in rodents. Here we sought to investigate the role o